Summary
Global Artemisinic Acid Market was valued at USD 501.34 Million in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 4.10% through 2029. The expansion of this market is driven by the extensive malaria burden in underdeveloped and developing economies, as well as by numerous research studies on malaria and initiatives spearheaded by prominent public organizations such as WHO and UNICEF. These organizations are actively working to raise awareness about malaria treatment and control its incidence worldwide.
Key Market Drivers
Malaria Eradication Efforts
Malaria eradication efforts have led to a heightened demand for ACTs, which are considered the frontline treatment for the disease. Artemisinin, derived from artemisinic acid, is a key component of these therapies. As the global health community strives to reduce the burden of malaria, the demand for ACTs has risen, consequently driving the demand for artemisinic acid as a primary precursor in their production. The emphasis on malaria eradication has prompted pharmaceutical companies, governments, and research organizations to invest in expanding the production capacities for artemisinin-based medicines. This has led to increased production of artemisinic acid, both from natural sources and through innovative biotechnological methods, in order to meet the rising demand for anti-malarial treatments. Malaria eradication efforts have underscored the importance of establishing stable and sustainable supply chains for essential medicines like artemisinin-based drugs. The cultivation of Artemisia annua plants and the extraction of artemisinic acid have become focal points in ensuring a consistent supply of anti-malarial medications. This has contributed to the growth of the artemisinic acid market as efforts are made to secure raw material sources. Global health organizations, governments, and pharmaceutical companies have joined forces to support collaborative initiatives aimed at eradicating malaria. These partnerships facilitate research, development, and production of artemisinin-based treatments, driving investment and innovation in the artemisinic acid market. Malaria-endemic regions have witnessed increased attention and resources as part of malaria eradication efforts. This focus on regions with high malaria prevalence has led to greater accessibility to artemisinin-based treatments, propelling demand for artemisinic acid and driving market growth. Malaria eradication efforts have accelerated research and development in the field of anti-malarial drugs. This includes advancements in production technologies, such as the use of synthetic biology to engineer microorganisms for artemisinic acid production. These technological innovations contribute to increased efficiency and scalability in the artemisinic acid market.
Pharmaceutical Industry Expansion
As the pharmaceutical industry expands, there is a growing emphasis on developing and producing effective medications to address global health challenges. Artemisinin-based combination therapies (ACTs) have gained prominence as vital tools in combating malaria, driving the demand for artemisinic acid, which is an essential precursor in artemisinin production. The pharmaceutical industry's expansion has led to substantial investments in research and development (RD) for new drugs and treatments. The focus on improving the efficiency and cost-effectiveness of artemisinin production has spurred innovative approaches, such as biotechnology and synthetic biology, which impact the production of artemisinic acid and its derivatives. As the pharmaceutical sector grows, so does the need to scale up production to meet the increasing demand for medications. Artemisinic acid, as a precursor for artemisinin, plays a crucial role in this supply chain. The pharmaceutical industry's expertise in optimizing production processes has contributed to the efficient and reliable production of artemisinic acid. The pharmaceutical industry's expansive distribution networks enable the widespread availability of anti-malarial drugs containing artemisinin. This extensive reach ensures that artemisinin-based treatments reach even remote areas affected by malaria, thereby driving the demand for artemisinic acid. Pharmaceutical companies continuously innovate by developing new formulations and dosage forms for medications. This innovation has led to the creation of various artemisinin-based drugs with improved efficacy, dosage regimens, and patient compliance. These advancements stimulate the market for artemisinic acid. As the pharmaceutical industry expands, collaborations between companies, research institutions, and governments become more prevalent. These partnerships contribute to knowledge exchange, technology transfer, and shared resources, ultimately leading to advancements in artemisinic acid production techniques and increased market growth. The pharmaceutical industry's expansion aids in addressing challenges such as drug resistance. By producing artemisinin-based therapies with high efficacy, the industry helps combat emerging resistance to anti-malarial drugs, thereby maintaining the relevance and demand for artemisinic acid.
Increasing Research and Development Advancements
Advancements in RD have led to the development of novel and more efficient production techniques for artemisinic acid. Synthetic biology, genetic engineering, and metabolic engineering approaches have been harnessed to engineer microorganisms capable of producing artemisinic acid. These techniques have not only streamlined production processes but also ensured a more consistent and scalable supply. RD efforts have focused on improving the yield and purity of artemisinic acid extraction. Through genetic optimization and cultivation practices, researchers have achieved higher yields of artemisinic acid from Artemisia annua plants. Additionally, purification techniques have been refined, resulting in higher-quality precursor material for artemisinin synthesis. RD innovations have driven cost efficiency in artemisinic acid production. This cost-effectiveness translates to more accessible and affordable artemisinin-based treatments, which are essential for malaria-endemic regions. The reduced production costs, in turn, support the growth of the artemisinic acid market. RD advancements have enabled the exploration of new artemisinin derivatives and analogs with potentially enhanced therapeutic properties. These derivatives expand the application of artemisinic acid beyond traditional anti-malarial medications, creating opportunities for diversification and market growth. The focus on sustainability has driven RD efforts to develop eco-friendly and renewable approaches to artemisinic acid production. Techniques that minimize the environmental impact, such as plant tissue culture and bioreactors, align with global sustainability goals and contribute to the market's growth. RD advancements in artemisinic acid production have accelerated drug development timelines. Faster and more efficient production methods enable quicker access to essential anti-malarial treatments, meeting urgent healthcare needs and spurring market growth. RD progress in artemisinic acid production technologies has led to the creation of valuable intellectual property. Licensing agreements and collaborations for technology transfer play a role in the commercialization and expansion of the artemisinic acid market.
Key Market Challenges
Supply Chain Vulnerability
Artemisinic acid is primarily sourced from the Artemisia annua plant, which is cultivated under specific agroclimatic conditions. Environmental factors such as weather variations, pests, and diseases can impact crop yields. Uncertain crop yields can lead to supply shortages and contribute to market instability. Global supply chains are subject to geopolitical disruptions, including trade restrictions, tariffs, and political instability in key sourcing regions. Such disruptions can interrupt the flow of artemisinic acid from production centers to manufacturing facilities, affecting the availability of artemisinin-based treatments. The heavy reliance on Artemisia annua plants as the primary source of artemisinic acid creates a single point of failure in the supply chain. Any disruption in plant cultivation, whether due to natural disasters or other factors, can have cascading effects on the production of artemisinin and related medicines. Artemisia annua cultivation is often seasonal, leading to cyclical fluctuations in artemisinic acid availability. This can result in challenges in maintaining a steady supply of artemisinin-based treatments throughout the year, particularly during peak malaria transmission seasons. Artemisinic acid cultivation is typically concentrated in malaria-endemic regions. Non-endemic regions may face challenges in accessing a consistent supply of artemisinic acid due to geographical limitations and limited infrastructure for cultivation and production. Climate change can alter agroclimatic conditions, affecting the growth and yield of Artemisia annua plants. Unpredictable weather patterns and changing temperature regimes may lead to reduced crop productivity, exacerbating supply chain vulnerabilities. Insufficient infrastructure for cultivation, harvesting, and processing of Artemisia annua plants can lead to inefficiencies in the supply chain. Lack of proper storage facilities, transportation options, and processing capabilities can hinder the timely and efficient delivery of artemisinic acid to manufacturers. Maintaining consistent quality and purity of artemisinic acid is essential for producing high-quality artemisinin-based medications. Supply chain vulnerabilities can compromise the quality control processes, leading to variability in the final product. Supply chain disruptions can lead to market instability and price fluctuations for artemisinic acid. This volatility can impact production costs and profitability, discouraging investment and innovation in the market.
Complex Production Processes
The complexity of production processes for artemisinic acid can contribute to elevated production costs. Sophisticated chemical synthesis methods, as well as the need for precise purification and quality control, can increase the overall expenses associated with producing artemisinic acid, affecting market viability. Intricate production methods can present challenges when scaling up production to meet increasing demand. Processes that work efficiently in laboratory settings might not be easily scalable for large-scale commercial production, leading to production bottlenecks. Complex production processes often require specialized technological expertise and skilled personnel. The availability of such expertise can be limited, potentially hindering the adoption and implementation of advanced production techniques. Elaborate production processes can result in longer production timelines from start to finish. Lengthy processing times can delay the availability of artemisinic acid for further conversion into artemisinin and subsequent drug formulation. The complexity of production processes may introduce variability in product quality and yield. Variability can impact the consistency of artemisinic acid supply, leading to challenges in maintaining the quality and efficacy of artemisinin-based medications. Complex production processes might require compliance with intricate regulatory standards and quality control measures. Meeting these standards can add a layer of complexity and potential delays to the production and distribution of artemisinic acid. The intricacies of production processes can serve as barriers to entry for new players in the market. Small and emerging companies might find it challenging to invest in the necessary infrastructure and expertise, limiting market competition and innovation. The complexity of production processes can slow down the pace of innovation. Developing and implementing new and more efficient production methods require significant time and resources, potentially delaying advancements in the field.
Key Market Trends
Synthetic Biology and Biotechnology
Synthetic biology enables the engineering of microorganisms to produce artemisinic acid through fermentation processes. This approach offers higher production yields and faster turnaround times compared to traditional plant cultivation. As a result, artemisinic acid can be produced more efficiently, meeting the growing demand for artemisinin-based treatments. Biotechnological methods allow for the scalable production of artemisinic acid, reducing the limitations posed by natural plant cultivation. This scalability ensures a stable and consistent supply of the precursor, mitigating supply chain vulnerabilities and enabling manufacturers to meet global healthcare needs. Synthetic biology and biotechnology align with sustainability goals by minimizing the environmental impact associated with traditional crop cultivation. These methods require less land, water, and pesticides, contributing to more eco-friendly and resource-efficient production of artemisinic acid. Natural sources of artemisinic acid, such as Artemisia annua, are constrained by agroclimatic conditions and limited cultivation capacities. Synthetic biology allows production in controlled environments, overcoming these limitations and expanding the potential for artemisinic acid production. Researchers are leveraging synthetic biology techniques to engineer microorganisms for optimal artemisinic acid production. Genetic modifications and metabolic engineering enable the development of high-yield strains that efficiently convert precursors into artemisinic acid, improving overall production efficiency. Synthetic biology and biotechnology trends encourage collaboration between academia, research institutions, and private sector companies. Knowledge and technology transfer accelerate innovation, leading to the development of cutting-edge production methods and fostering a dynamic market ecosystem. Biotechnology allows for precise genetic modifications, enabling the tailoring of production strains for specific outputs and properties. This customization opens doors to the creation of specialized artemisinic acid variants with enhanced characteristics. The potential for groundbreaking advancements in artemisinic acid production through synthetic biology has attracted significant investments and funding. This influx of resources fosters innovation and market growth by supporting research and commercialization efforts. The integration of synthetic biology and biotechnology aligns with global efforts to address healthcare challenges sustainably. By offering a more efficient and environmentally friendly approach to artemisinic acid production, these trends contribute to the broader goal of global health and well-being.
Diversification of End Products
The diversification of artemisinic acid applications expands the market's potential beyond anti-malarial drugs. By addressing a broader range of industries, including cosmetics, nutraceuticals, and pharmaceuticals, the market gains access to new customer segments and revenue streams. Relying solely on the production of artemisinin for anti-malarial treatments can expose the market to risks such as supply chain vulnerabilities and market fluctuations. Diversifying end products helps mitigate risks by reducing dependence on a single application, promoting market resilience. The introduction of new artemisinic acid derivatives and applications allows companies to differentiate themselves in a competitive market. Innovative products cater to specific consumer needs and demands, enhancing a company's brand and market positioning. Diversified end products align with health and wellness trends, driving demand for natural and plant-derived ingredients. Nutraceuticals and dietary supplements benefit from the inclusion of artemisinic acid, leveraging its potential health benefits beyond malaria treatment. Artemisinic acid's antioxidant properties make it a valuable ingredient in cosmetics and skincare products. Its potential to enhance skin health and reduce oxidative stress positions it as a sought-after ingredient in the personal care industry. Researchers are exploring the use of artemisinic acid in various scientific and biotechnological applications. The compound's unique properties make it valuable for use in laboratory settings and research experiments, further expanding its utility. Diversification of end products enhances the market's resilience during health crises. While anti-malarial treatments remain crucial, the availability of other products helps balance demand and supply dynamics during emergencies.
Segmental Insights
Applications Insights
Based on the Applications, the antimalarial tablets segment is anticipated to witness substantial market growth throughout the forecast period.
The use of antimalarial tablets drives the demand for artemisinin, which is a primary ingredient in artemisinin-based combination therapies (ACTs). As malaria remains a significant global health challenge, the sustained demand for effective antimalarial treatments contributes to the growth of the artemisinic acid market. The consistent and ongoing demand for antimalarial tablets provides market stability and predictability for artemisinic acid producers. This stability encourages investments in research, production, and innovation, fostering a conducive environment for market growth. The continuous need for effective antimalarial treatments incentivizes ongoing research and innovation in the artemisinic acid market. Companies and research institutions are motivated to improve production techniques, optimize supply chains, and enhance the overall efficiency of artemisinin-based therapies. Antimalarial tablets are a cornerstone of global health initiatives aimed at combating malaria. These initiatives drive funding, collaborations, and partnerships that support artemisinic acid production, ensuring a steady supply of essential medications. The demand for antimalarial tablets encourages the integration of new technologies in artemisinin production. Synthetic biology, biotechnology, and advanced extraction methods are adopted to streamline production processes and enhance the efficiency of artemisinic acid production. The success of antimalarial tablets opens doors to explore applications of artemisinic acid beyond malaria treatment. As research expands, the compound's potential for other therapeutic uses, such as anticancer properties, could drive additional market growth. The demand for antimalarial tablets aligns regulatory frameworks to ensure the quality, safety, and efficacy of artemisinin-based treatments. Regulatory compliance contributes to a robust and trustworthy market environment. Partnerships between pharmaceutical companies, governments, and global health organizations leverage the demand for antimalarial tablets to drive joint initiatives. These collaborations stimulate investments, research, and knowledge-sharing, boosting the growth of the artemisinic acid market.
Regional Insights
Middle East Africa, specifically the Artemisinic Acid Market, dominated the market in 2023, primarily due to The MEA region bears a substantial malaria burden, with several countries facing high transmission rates. This prevalence drives the demand for effective antimalarial treatments, including those derived from artemisinic acid. The region's demand contributes significantly to the global consumption of artemisinin-based medications. Some countries in the MEA region have suitable agroclimatic conditions for cultivating Artemisia annua, the plant source of artemisinic acid. Leveraging this potential for local production can enhance the region's contribution to the global artemisinic acid supply chain. The growth of the artemisinic acid market in the MEA region aligns with economic development initiatives. Improving access to essential medicines, including artemisinin-based treatments, contributes to healthcare advancements and demonstrates the region's commitment to public health. Governments and international organizations in the MEA region are actively involved in public health initiatives to combat malaria. These initiatives drive partnerships, funding, and collaborative efforts that support the growth of the artemisinic acid market. The regulatory landscape in the MEA region can influence the ease of production, distribution, and access to artemisinic acid and its derivatives. Harmonizing regulations and ensuring compliance can facilitate market growth and streamline cross-border trade. Collaborations between countries within the MEA region and international organizations strengthen the artemisinic acid market. Regional partnerships can drive knowledge-sharing, technology transfer, and sustainable supply chain development. Raising public awareness about malaria and the availability of artemisinin-based treatments is crucial in the MEA region. Educational campaigns promote early diagnosis, treatment adherence, and preventive measures, supporting the growth of the market.
Key Market Players
Sanofi SA
KPC Pharmaceuticals, Inc
Guilin Pharmaceutical Co., Ltd
Calyx Chemicals and Pharmaceuticals Ltd.
Novartis AG
Ipca Laboratories Ltd.
Cipla Inc.
Shin Poong Pharm Co., Ltd.
Rupus Global Limited
AdvacarePharma
Report Scope:
In this report, the Global Artemisinic Acid Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Artemisinic Acid Market,By Type:
oTotal Synthesis
oSemi synthesis
Artemisinic Acid Market,By Applications:
oAntimalarial Injections
oAntimalarial Tablets
Artemisinic Acid Market, By Region:
oNorth America
§United States
§Canada
§Mexico
oEurope
§France
§United Kingdom
§Italy
§Germany
§Spain
oAsia-Pacific
§China
§India
§Japan
§Australia
§South Korea
oSouth America
§Brazil
§Argentina
§Colombia
oMiddle East Africa
§South Africa
§Saudi Arabia
§UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Artemisinic Acid Market.
Available Customizations:
Global Artemisinic Acid market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
ページTOPに戻る
Table of Contents
1.Product Overview
1.1.Market Definition
1.2.Scope of the Market
1.2.1.Markets Covered
1.2.2.Years Considered for Study
1.2.3.Key Market Segmentations
2.Research Methodology
2.1.Objective of the Study
2.2.Baseline Methodology
2.3.Key Industry Partners
2.4.Major Association and Secondary Sources
2.5.Forecasting Methodology
2.6.Data Triangulation Validation
2.7.Assumptions and Limitations
3.Executive Summary
3.1.Overview of the Market
3.2.Overview of Key Market Segmentations
3.3.Overview of Key Market Players
3.4.Overview of Key Regions/Countries
3.5.Overview of Market Drivers, Challenges, Trends
4.Voice of Customer
5.GlobalArtemisinic Acid MarketOutlook
5.1.Market Size Forecast
5.1.1.By Value
5.2.Market Share Forecast
5.2.1.By Type (Total Synthesis,Semi synthesis)
5.2.2.By Applications (Antimalarial Injections, Antimalarial Tablets)
5.2.3.By Region (Middle East Africa, Asia Pacific, South America, Europe, North America)
5.2.4.By Company (2023)
5.3.Market Map
5.3.1 By Type
5.3.2 By Applications
5.3.3 By Region
6.Middle East and Africa Artemisinic Acid Market Outlook
6.1.Market Size Forecast
6.1.1.By Value
6.2.Market Share Forecast
6.2.1.By Type (Total Synthesis, Semi synthesis)
6.2.2.By Applications (Antimalarial Injections, Antimalarial Tablets)
6.2.3.By Country
6.3.MEA: Country Analysis
6.3.1.South Africa Artemisinic Acid Market Outlook
6.3.1.1.Market Size Forecast
6.3.1.1.1.By Value
6.3.1.2.Market Share Forecast
6.3.1.2.1.ByType
6.3.1.2.2.By Applications
6.3.2.Saudi Arabia Artemisinic Acid Market Outlook
6.3.2.1.Market Size Forecast
6.3.2.1.1.By Value
6.3.2.2.Market Share Forecast
6.3.2.2.1.ByType
6.3.2.2.2.By Applications
6.3.3.UAE Artemisinic Acid Market Outlook
6.3.3.1.Market Size Forecast
6.3.3.1.1.By Value
6.3.3.2.Market Share Forecast
6.3.3.2.1.ByType
6.3.3.2.2.By Applications
7.Asia-Pacific Artemisinic Acid Market Outlook
7.1.Market Size Forecast
7.1.1.By Value
7.2.Market Share Forecast
7.2.1.By Type (Total Synthesis, Semi synthesis)
7.2.2.By Applications (Antimalarial Injections, Antimalarial Tablets)
7.2.3.By Country
7.3.Asia-Pacific: Country Analysis
7.3.1.China Artemisinic Acid Market Outlook
7.3.1.1.Market Size Forecast
7.3.1.1.1.By Value
7.3.1.2.Market Share Forecast
7.3.1.2.1.ByType
7.3.1.2.2.By Applications
7.3.2.India Artemisinic Acid Market Outlook
7.3.2.1.Market Size Forecast
7.3.2.1.1.By Value
7.3.2.2.Market Share Forecast
7.3.2.2.1.ByType
7.3.2.2.2.By Applications
7.3.3.Japan Artemisinic Acid Market Outlook
7.3.3.1.Market Size Forecast
7.3.3.1.1.By Value
7.3.3.2.Market Share Forecast
7.3.3.2.1.ByType
7.3.3.2.2.By Applications
7.3.4.South Korea Artemisinic Acid Market Outlook
7.3.4.1.Market Size Forecast
7.3.4.1.1.By Value
7.3.4.2.Market Share Forecast
7.3.4.2.1.ByType
7.3.4.2.2.By Applications
7.3.5.Australia Artemisinic Acid Market Outlook
7.3.5.1.Market Size Forecast
7.3.5.1.1.By Value
7.3.5.2.Market Share Forecast
7.3.5.2.1.ByType
7.3.5.2.2.By Applications
8.South America Artemisinic Acid Market Outlook
8.1.Market Size Forecast
8.1.1.By Value
8.2.Market Share Forecast
8.2.1.By Type (Total Synthesis, Semi synthesis)
8.2.2.By Applications (Antimalarial Injections, Antimalarial Tablets)
8.2.3.By Country
8.3.South America: Country Analysis
8.3.1.Brazil Artemisinic Acid Market Outlook
8.3.1.1.Market Size Forecast
8.3.1.1.1.By Value
8.3.1.2.Market Share Forecast
8.3.1.2.1.ByType
8.3.1.2.2.By Applications
8.3.2.Argentina Artemisinic Acid Market Outlook
8.3.2.1.Market Size Forecast
8.3.2.1.1.By Value
8.3.2.2.Market Share Forecast
8.3.2.2.1.ByType
8.3.2.2.2.By Applications
8.3.3.Colombia Artemisinic Acid Market Outlook
8.3.3.1.Market Size Forecast
8.3.3.1.1.By Value
8.3.3.2.Market Share Forecast
8.3.3.2.1.ByType
8.3.3.2.2.By Applications
9.Europe Artemisinic Acid Market Outlook
9.1.Market Size Forecast
9.1.1.By Value
9.2.Market Share Forecast
9.2.1.By Type (Total Synthesis, Semi synthesis)
9.2.2.By Applications (Antimalarial Injections, Antimalarial Tablets)
9.2.3.By Country
9.3.Europe: Country Analysis
9.3.1.France Artemisinic Acid Market Outlook
9.3.1.1.Market Size Forecast
9.3.1.1.1.By Value
9.3.1.2.Market Share Forecast
9.3.1.2.1.ByType
9.3.1.2.2.By Applications
9.3.2.Germany Artemisinic Acid Market Outlook
9.3.2.1.Market Size Forecast
9.3.2.1.1.By Value
9.3.2.2.Market Share Forecast
9.3.2.2.1.ByType
9.3.2.2.2.By Applications
9.3.3.United Kingdom Artemisinic Acid Market Outlook
9.3.3.1.Market Size Forecast
9.3.3.1.1.By Value
9.3.3.2.Market Share Forecast
9.3.3.2.1.ByType
9.3.3.2.2.By Applications
9.3.4.Italy Artemisinic Acid Market Outlook
9.3.4.1.Market Size Forecast
9.3.4.1.1.By Value
9.3.4.2.Market Share Forecast
9.3.4.2.1.ByType
9.3.4.2.2.By Applications
9.3.5.Spain Artemisinic Acid Market Outlook
9.3.5.1.Market Size Forecast
9.3.5.1.1.By Value
9.3.5.2.Market Share Forecast
9.3.5.2.1.ByType
9.3.5.2.2.By Applications
10.North America Artemisinic Acid Market Outlook
10.1.Market Size Forecast
10.1.1.By Value
10.2.Market Share Forecast
10.2.1.By Type (Total Synthesis, Semi synthesis)
10.2.2.By Applications (Antimalarial Injections, Antimalarial Tablets)
10.2.3.By Country
10.3.North America: Country Analysis
10.3.1.United States Artemisinic Acid Market Outlook
10.3.1.1.Market Size Forecast
10.3.1.1.1.By Value
10.3.1.2.Market Share Forecast
10.3.1.2.1.ByType
10.3.1.2.2.By Applications
10.3.2.Canada Artemisinic Acid Market Outlook
10.3.2.1.Market Size Forecast
10.3.2.1.1.By Value
10.3.2.2.Market Share Forecast
10.3.2.2.1.ByType
10.3.2.2.2.By Applications
10.3.3.Mexico Artemisinic Acid Market Outlook
10.3.3.1.Market Size Forecast
10.3.3.1.1.By Value
10.3.3.2.Market Share Forecast
10.3.3.2.1.ByType
10.3.3.2.2.By Applications
11.Market Dynamics
11.1.Drivers
11.2.Challenges
12.Market Trends Developments
12.1.Recent Development
12.2.Mergers Acquisitions
12.3.Product Launches
13.Global Artemisinic Acid Market: SWOT Analysis
14.Porter’s Five Forces Analysis
14.1.Competition in the Industry
14.2.Potential of New Entrants
14.3.Power of Suppliers
14.4.Power of Customers
14.5.Threat of Substitute Products
15.Competitive Landscape
15.1.Sanofi SA
15.1.1.Business Overview
15.1.2.Product Offerings
15.1.3.Recent Developments
15.1.4.Financials (As Reported)
15.1.5.Key Personnel
15.1.6.SWOT Analysis
15.2.KPC Pharmaceuticals, Inc
15.3.Guilin Pharmaceutical Co., Ltd
15.4.Calyx Chemicals and Pharmaceuticals Ltd.
15.5.Novartis AG
15.6.Ipca Laboratories Ltd.
15.7.Cipla Inc.
15.8.Shin Poong Pharm Co., Ltd.
15.9.Rupus Global Limited
15.10.AdvacarePharma
16.Strategic Recommendations
17.About Us Disclaimer
